Top Story
Big research effort blueprints bacteria in the gut
More than 100 researchers teamed up over two years pieced together a genetic blueprint of the bacteria that's found in the human digestive tract. Their work cataloguing the sequencing data on 124 adults should help shape a new generation of drugs for ulcers and inflammatory diseases, while illuminating how the same kind of basic sequencing programs can help influence development work in other disease areas. ArticleEditor's Corner
Experts discuss challenges, promises of personalized medicine
Personalized medicine holds tremendous promise for drugmakers, clinicians and patients alike--the market is estimated at about $232 billion and is projected to grow 11 percent annually, according to a PriceWaterhouseCoopers' report. But it also presents players with opportunities and challenges--both on the commercial and regulatory fronts. Report ⇒From The Network
Also Noted
Stem Cell Research
> Entest BioMedical has announced the creation of 3 bone marrow derived stem cell lines useful for optimizing laser intensities and wavelengths in laser enhanced stem cell therapy. Release
> Human embryonic stem cells have received FDA approval for testing as a treatment for a rare blindness syndrome. Olympic and Paralympic skier Brian McKeever is the best-known victim of the disease, which has no treatment. Item
> The Pahang government will proceed with plans to set up a stem cell research hub despite questions being raised on the effectiveness of stem cell treatment, Mentri Besar Datuk Seri Adnan Yaakob said. Story
Genetics
Read more >>Press Releases
- NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk CV patients with impaired glucose tolerance
- Manhattan Pharmaceuticals Completes Merger Transaction With Ariston Pharmaceuticals
- Progenics Pharmaceuticals, Inc. (PGNX) to Advance Oral Methylnaltrexone into Late Stage Clinical Development
- TaiGen Biotechnology Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints
- Ipsen Grants Rhythm Pharmaceuticals Obesity Treatment Licence; Ipsen will Receive up to $80 Million
- MiddleBrook Pharmaceuticals Reports Fourth Quarter 2009 and Full-Year Results; Announces Reduction in Force; Engages Broadpoint




